Ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An unresolved issue

Int J Cardiol. 2017 Dec 15:249:77-78. doi: 10.1016/j.ijcard.2017.09.180.

Authors

Gianluigi Savarese¹, Lars H Lund²

Affiliations

¹ Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address: gianluigi.savarese@ki.se.
² Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.

PMID: 29121762
DOI: 10.1016/j.ijcard.2017.09.180

No abstract available

Publication types

Editorial
Comment

MeSH terms

Acute Coronary Syndrome*
Adenosine / analogs & derivatives
Humans
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors
Prasugrel Hydrochloride*
Purinergic P2Y Receptor Antagonists
Ticagrelor
Ticlopidine
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Prasugrel Hydrochloride
Ticagrelor
Adenosine
Ticlopidine